SLC16A13 and type 2 diabetes mellitus: SLC16A13 is a lactate transporter expressed at the plasma membrane and a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (Schumann et al., 2021), while its role in tumor needs to be further explored.